From python to purse: How enterprising hunters are honoring snakes by using their skins Amy Bennett Williams Naples Daily News 0:05 ...

Amy & T.J., I am 60 years old and my husband of less than two years has been telling his family and friends — in my presence — that he married me out of a sense of obligation.

MIT and Recursion have released Boltz-2, the first biomolecular co-folding model that simultaneously predicts molecular structure and binding affinity with remarkable accuracy, approaching that of ...

In line with MIT and Recursion’s commitment to making AI tools accessible for drug developers, Boltz-2 will be open-sourced under an MIT license, making the model, weights, and training pipeline ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but ...

Our Nintendo Switch 2 beginners guide is here to help you make the most of your console, whether this is your first time, or if you've already had a run with the original.

Once a user with the same Nintendo Account has been created on the Nintendo Switch 2, you can select the Virtual Game Cards tab in the Home Menu on the system you wish to load a game onto from the ...

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...

Hi there, I'm using Unsloth's SFT library and it's been fairly buggy lately, and today it no longer functions. This code, from unsloth import FastLanguageModel import torch max_seq_length = 4096 # ...

Recursion also announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1/2 clinical trial of REC-4539, a potential best-in-class LSD1 ...

Recursion Pharmaceuticals (RXRX 1.15%) is a clinical-stage biotech that may have that level of potential. The company harnesses artificial intelligence (AI) for drug discovery, promising to ...

Recursion saw a similar safety and tolerability profile across the placebo group and two REC-994 doses over 12 months of treatment, causing the study to meet its primary endpoint.